REGISTER
LOG IN
HOME
RESOURCES
Publications
Conference Calendar
Past Quiz Results
ARTICLES
First-ever Study of Mycology Lab Practices in Asia
Fereydounia khargensis: A New Opportunistic Yeast Reported from Malaysia
9 Years of MMTN: Improving Fungal Disease Management in Asia Pacific
Echinocandins: Clinicians' Guide
Fungemia blood culture media
Deep dermatophytosis
AFWG Education Module 4: Is Antifungal Susceptibility Testing Useful for Clinical Management?
AFWG Education Module 5: TDM of Antifungal Agents - Essential or Optional?
AFWG Education Module 6: Antifungal Stewardship
Itraconazole: A Quick Guide for Clinicians
Evolving Fungal Landscape in Asia
Laboratory Diagnosis of Pythiosis
ICMR Issues C. auris Advisory
Strengths and Limitations of Imaging for Diagnosis of IFI
Candidemia: Lessons Learned from Asian Studies for Intervention
Pivotal Asian Invasive Mold Study
Mycetoma in Asia: Still veiled in mystery
Cryptococcosis
New Antifungal Agents
Making Precise Diagnoses: Experience from the Laboratory Skills Enhancement Course
AFWG Online Education Module 3: Optimizing Dosing in IFI Management
AFWG Online Education Module 2: Antifungal Prophylaxis in Solid Organ Transplantation
AFWG Education Module 1: The Value of Clinical Mycology Laboratories
Cryptococcosis in HIV and non-HIV infected patients
Human Pythiosis
AFWGOnline Privacy Policy has been Updated
Recent Advances of Fungal Diagnostics in Asian Laboratories
Deep Dermatophytosis: A Case Report
Emerging yeast infections in Asia
Championing Medical Mycology: Thoughts on the AFWG Laboratory Skills Enhancement Course
Mucormycosis and Pythiosis – New Insights
AML and the high risk of multiple infectious complications
Do We Need Modification of Recent IDSA & ECIL Guidelines while Managing Patients in Asia?
A hospital’s experience with candidemia and empirical therapy
Fungal Academy 2015
Fluconazole in 2015
Fungal isolation protocol
Influencing Aspergillus
Fungal Asthma
Aspergillus
Laboratory Diagnosis of IPA
Two-Hot-to-Handle
Voriconazole
Educational Organizations
Literature Updates
 

Articles

Do We Need Modification Of Recent IDSA & ECIL Guidelines While Managing Patients In Asia?

Share this
page



Share
this page

Dr Louis Chai
Senior Consultant and Associate Professor
University Medicine Cluster
National University Health System
Singapore

Guidelines are very important in the management of fungal infections. They play a crucial role in summarizing the current evidence base, standardizing care and improving outcomes. However, there are many reasons why clinicians in Asia (or, indeed, elsewhere in the world) might want to deviate from recommendations:

  • The importance of individualized clinical judgment over generic pathways;
  • Differences between trial data and ‘real-life’ practice;
  • Local epidemiology and resistance patterns;
  • Varying patient demographics;
  • Drug intolerance; and
  • Cost concerns.

Invasive candidiasis

According to both the Infectious Diseases Society of America (IDSA) and the European Conference on Infections in Leukemia (ECIL), echinocandins are now the recommended initial therapy for candidemia in both neutropenic and non-neutropenic patients.1,2 There remains an allowance for the use of azoles and liposomal amphotericin B in some circumstances.

However, in an Asian context, local circumstances may dictate some divergence from guidelines. In particular, epidemiology may differ substantially in this region compared with North America and Europe – most notably in a higher incidence of Candida tropicalis and a lower incidence of C. glabrata.3,4

In addition, cost is a concern. A recent Asian study assessed the cost-effectiveness of individual echinocandins (caspofungin, micafungin and anidulafungin) versus non-echinocandins for C. albicans and non-albicans spp., taking into account the probability of treatment success, mortality rates, adverse drug events, etc.5 Importantly, the study found that echinocandins – particularly anidulafungin – were cost-effective compared with other therapies.

Invasive aspergillosis

In recent guidance from IDSA and ECIL, recommendations for the primary therapy of invasive aspergillosis (IA) were based largely around voriconazole and isavuconazole.1,6 ECIL-6 recommends against first-line use of amphotericin B deoxycholate on the grounds of low efficacy and high toxicity.6

However, the reality of IA management may come down to whether or not a given center can take a diagnosis-driven approach, based on the latest tools and rapid diagnostic turnaround times. For many centers in Asia, this is not yet possible because the capacity to investigate the underlying etiology is limited. Instead, an empiric approach must be taken, based on the treatment of a presumed fungal infection, triggered by persistent fever in a high-risk (neutropenic) patient. The choice of empiric therapy may include agents such as voriconazole, fluconazole, liposomal amphotericin B and caspofungin.

References

  1. Pappas PG, et al. Clin Infect Dis 2016;62:e1-e50.
  2. Tissot F, et al. Haematologica 2017;102:433-444.
  3. Falagas ME, et al. Int J Infectious Dis 2010;14:e954-e966.
  4. Pfaller MA, et al. J Clin Microbiol 2011;49:396-399.
  5. Ou HT, et al. BMC Infect Dis 2017;17:481.
  6. Patterson TF, et al. Clin Infect Dis 2016;63:e1-e60.
SIGN UP FOR NEWSLETTER
SIGN UP

This field is required. Please enter your email address.
Thank you for signing up for the AFWG newsletter.
You have previously subscribed for AFWG newsletter.